10 results about "Probenecid" patented technology

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The present disclosure relates to a combination of valproic acid or a pharmaceutically acceptable salt thereof, a β-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing disease using this combination.

Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.

Compositions and methods of treating a coronavirus infection in a subject are provided. The methods generally include administering to the subject an effective amount of a probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and / or prophylactic. The amount of probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof can be effective, for example, to reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with the virus, or a combination thereof. In preferred embodiments, the virus is a severe acute respiratory syndrome-associated coronavirus, such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-associated coronavirus, such as MERS-CoV, or a coronavirus that causes the common cold.

The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated dermatological diseases or conditions.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

The invention relates to a preparation method for salifying and freeze-drying probenecid, which is characterized by comprising the following steps: reacting probenecid and a salt-forming agent in injection water to form salt, adding a pH regulator to regulate the pH value, adding absolute ethyl alcohol, adsorbing and decolorizing with activated carbon, filtering, and freeze-drying to obtain the product, the probenecid comprises probenecid, sodium hydroxide and sodium carbonate according to a molar ratio of 1: 1: 0.01, a solvent is injection water containing 3%-5% of ethanol, and freeze-drying comprises pre-freezing, annealing, heating to melt small ice crystals, and re-freezing. The probenecid sodium freeze-dried powder is good in appearance property, stable in salt forming rate, controllable in pH and capable of improving the redissolution time, the product freeze-drying process efficiency is improved, and it is guaranteed that the product quality is controllable. The process is simple and suitable for industrial production.

The invention discloses a human trophoblast organ-like model and a construction method and application thereof. The method comprises the following steps: firstly, digesting and separating trophoblast cells from human placenta villus, inoculating the trophoblast cells into matrigel, and adding an ADMEM / F12 culture medium containing specific growth factors for culturing to form trophoblast-like organs; then morphological observation is carried out, and expression of P-gp, BCRP and MRP1 / 2 is detected from mRNA and protein level to carry out model verification; a co-incubation method is adopted, a plurality of ABC transporter specific substrates are adopted, and the influence of verapamil, KO143 and probenecid on the transportation of the ABC transporter specific substrates is researched; and finally, the method is applied to evaluation of substrate transport inhibition of a clinical drug on the ABC transporter protein. The human trophoblast organ model is constructed for the first time and is applied to ABC transporter mediated drug transport research, the operation method is efficient and rapid, and the organ model can be widely applied to in-vitro high-throughput screening of clinical drugs on ABC transporter inhibitors. The method has a wide application prospect.